San Diego Life Sciences Roundup: Trius, CoDa, Zacharon, & More
(Page 2 of 2)
its new drug application later this year. Trius said the antibiotic, tedizolid phosphate, has been undergoing Phase 3 clinical trials to treat skin infections caused by MRSA, the multi-drug resistant strain Staphylococcus aureus bacteria. The special designation means the FDA review will take about eight months, instead of the standard 10 months or longer. If approved, tedizolid also would get an additional five years exclusivity against generic competitors.
San Diego’s Tandem Diabetes Care said it plans to develop a new dual-chamber infusion pump for patients with type 1 diabetes under a new partnership with JDRF, under the New York non-profit group’s multi-year artificial pancreas project. In a statement, Tandem Diabetes said the agreement is intended to accelerate the development of a next-generation, fully automated artificial pancreas system using therapies in conjunction with insulin. The JDRF was previously known as the Juvenile Diabetes Research Foundation.
—San Diego-based Independa said its Web-based services designed to help seniors live independently is now available on Samsung’s Galaxy tablet. The startup’s online eldercare services also became available recently on LG Pro:Centric Healthcare TVs under the partnership that Independa established with LG Electronics USA just over a year ago.
—San Diego’s GreatCall, the mobile virtual network operator that provides wireless services, apps, and Jitterbug and 5Star handsets, said it introduced “Urgent Care,” a medical app for iOS and Android devices. The 24/7 service enables users to discuss a medical ailment or injury with a registered nurse and other medical specialists, including doctors.